FCGR3A基因多态性对匈牙利类风湿关节炎患者利妥昔单抗疗效的影响
该研究纳入52例匈牙利类风湿关节炎患者,采用实时PCR检测FCGR3A基因多态性,分析其与利妥昔单抗治疗后DAS28变化的关系。结果显示VF杂合子DAS28下降幅度显著大于FF纯合子,VV和VF基因型患者达到低疾病活动度的比例显著高于FF患者。提示FCGR3A多态性可能预测利妥昔单抗的疗效。
要点
- VF杂合子DAS28下降显著大于FF纯合子(p=0.032)。
- VV和VF患者达低疾病活动度比例显著高于FF(p=0.030和p=0.015)。
- 携带V等位基因可能与更好的治疗反应相关。
核心结论
- FCGR3A基因多态性可能预测利妥昔单抗治疗类风湿关节炎时更有效的疾病活动度下降。
- 携带V等位基因可能与匈牙利类风湿关节炎患者更好的治疗反应相关。
研究设计与样本
- 研究纳入52例匈牙利类风湿关节炎患者,其中男性6例、女性46例。
- 采用实时PCR方法对患者外周血样本进行FCGR3A基因分型。
主要发现
- FCGR3A基因型分布为VV 8例、VF 34例、FF 10例。
- VV、VF和FF基因型患者DAS28下降分别为1.98±0.54(治疗前后p=0.008)、2.07±0.23(p<0.001)和1.59±0.52(p=0.014)。
- VF杂合子与FF纯合子之间DAS28下降差异显著(p=0.032),杂合子与全部纯合子(VV+FF)之间差异亦显著(p=0.017)。
- 达到低疾病活动度的患者比例:VV为62.5%(p=0.030)、VF为64.7%(p=0.015),均显著高于FF的30.0%。
临床怎么用
- 在匈牙利类风湿关节炎患者中,FCGR3A VF或VV基因型可能提示利妥昔单抗治疗后疾病活动度下降更明显。
- FCGR3A FF基因型患者利妥昔单抗治疗后达到低疾病活动度的比例较低,临床决策时可参考基因分型信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) treatment includes the use of the anti-CD20 monoclonal antibody rituximab (RTX). RTX acts through Fcγ-receptors (FCGR) on effector natural killer cells and macrophages and it can be administered effectively in RA and in lymphomas. Based on the results of in vitro experiments, its efficacy may depend of FCGR gene polymorphisms in both diseases. AIM: As genetic background of diseases and therapeutic efficacy (pharmacogenetics) may vary among different geographical regions, we wished to assess possible relationships between FCGR3A polymorphism and the therapeutic outcome of RTX therapy in a Hungarian RA cohort. PATIENTS AND METHODS: Altogether, 52 patients, 6 men and 46 women, were included in the study. Peripheral blood samples were used to determine FCGR3A polymorphism by genotyping using real-time PCR method. RESULTS: The distribution of FCGR3A genotypes was 8 VV, 34 VF and 10 FF. Disease activity score 28 (DAS28) reductions in patients with VV, VF and FF genotypes were 1.98±0.54 (p=0.008 between DAS28 before and after treatment), 2.07±0.23 (p<0.001) and 1.59±0.52 (p=0.014), respectively. Significant differences in DAS28 reductions on treatment were found between VF heterozygotes and FF homozygotes (p=0.032), as well as between heterozygotes and all (VV+FF) homozygotes (p=0.017). Furthermore, significantly more VV (62.5%; p=0.030) and VF (64.7%; p=0.015) patients achieved low disease activity compared with FF subjects (30.0%). CONCLUSION: Our results suggest that FCGR3A polymorphism may predict more effective disease activity reduction by RTX. Furthermore, carrying the V allele may also be associated with better therapeutic response in Hungarian patients with RA.
引用
- Pál I, Szamosi S, Hodosi K, et al. Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. RMD Open. 2017. PMID: 29177079. doi:10.1136/rmdopen-2017-000485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。